Treatment with direct‐acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma

Abstract

Achieving SVR with DAA regimens was associated with a significant risk reduction in HCC. However, this risk remained high in patients with advanced fibrosis, thus demanding continuous surveillance strategies in this population.